Immunogenicity and Efficacy of the Live Attenuated, Recombinant Chikungunya Virus Vaccine MV-CHIK in Non Human Primates

Project: Other project

StatusFinished
Effective start/end date2/1/1611/1/17

Funding

  • Themis Bioscience GmbH: $173,195.07